Patents by Inventor Richard Peter Charles
Richard Peter Charles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7985740Abstract: The invention provides novel compounds which are agonists of the adenosine 2A receptor along with pharmaceutical compositions thereof, and methods of administering such compounds.Type: GrantFiled: July 17, 2006Date of Patent: July 26, 2011Assignee: Glaxo Group LimitedInventors: David George Allen, Michael David Barker, Richard Peter Charles Cousins
-
Publication number: 20100179139Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.Type: ApplicationFiled: May 29, 2008Publication date: July 15, 2010Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
-
Patent number: 7737126Abstract: A compound of formula (I) and salts and solvates thereof are disclosed. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.Type: GrantFiled: May 23, 2005Date of Patent: June 15, 2010Assignee: Glaxo Group LimitedInventors: Philip Blatcher, Richard Peter Charles Cousins, Derek Norman Evans
-
Publication number: 20100035917Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.Type: ApplicationFiled: September 20, 2007Publication date: February 11, 2010Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
-
Publication number: 20080214581Abstract: A compound of formula (I): wherein R1-R3 are as defined in the specification, and compositions, combinations, and methods of manufacture, and methods of treatment of inflammatory diseases, using the same.Type: ApplicationFiled: July 17, 2006Publication date: September 4, 2008Inventors: David George Allen, Michael David Barker, Richard Peter Charles Cousins
-
Publication number: 20080176891Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.Type: ApplicationFiled: September 20, 2007Publication date: July 24, 2008Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
-
Publication number: 20080146606Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.Type: ApplicationFiled: September 20, 2007Publication date: June 19, 2008Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
-
Publication number: 20080132526Abstract: The present invention provides a compound of formula (I) and salts and solvates thereof. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.Type: ApplicationFiled: May 23, 2005Publication date: June 5, 2008Applicant: GLAXO GROUP LIMITEDInventors: Philip Blatcher, Richard Peter Charles Cousins, Derek Norman Evans
-
Patent number: 6677316Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.Type: GrantFiled: August 13, 2002Date of Patent: January 13, 2004Assignee: SmithKline Beecham CorporationInventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 6610665Abstract: There are disclosed according to the invention, compounds of formula (I) wherein R1, R2 and R3 are defined in the specification. Additionally, processes of preparing the compounds of formula (I), formulations containing same, and the administration of said compounds or formulations thereof in the treatment of inflammatory diseases are also disclosed.Type: GrantFiled: August 29, 2000Date of Patent: August 26, 2003Assignee: Smithkline Beecham CorporationInventors: David Edmund Bays, Chuen Chan, Caroline Mary Cook, Brian Cox, Richard Peter Charles Cousins, Hazel Joan Dyke, Frank Ellis, Joanna Victoria Geden, Stephen Swanson
-
Publication number: 20030096788Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.Type: ApplicationFiled: August 13, 2002Publication date: May 22, 2003Applicant: Glaxo Wellcome Inc.Inventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 6534486Abstract: A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.Type: GrantFiled: February 28, 2001Date of Patent: March 18, 2003Assignee: SmithKline Beecham CorporationInventors: David George Allen, Chuen Chan, Caroline Mary Cook, Richard Peter Charles Cousins, Brian Cox, Hazel Joan Dyke, Frank Ellis, Joanna Victoria Geden, Heather Hobbs, Suzanne Elaine Keeling, Alison Judith Redgrave, Stephen Swanson, Caroline Whitworth, David Bays
-
Patent number: 6495528Abstract: A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.Type: GrantFiled: February 20, 2001Date of Patent: December 17, 2002Assignee: SmithKline Beecham CorporationInventors: David George Allen, Chuen Chan, Richard Peter Charles Cousins, Brian Cox, Joanna Victoria Geden, Heather Hobbs, Suzanne Elaine Keeling, Alison Judith Redgrave, Thomas Davis Roper, IV, Shiping Xie
-
Patent number: 6492348Abstract: A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.Type: GrantFiled: March 6, 2001Date of Patent: December 10, 2002Assignee: SmithKline Beecham CorporationInventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 6455510Abstract: A compound of formula (I) which is an agonist at the adenosine A1 receptor wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the adenosine A1 receptor.Type: GrantFiled: June 15, 2000Date of Patent: September 24, 2002Assignee: SmithKline Beecham CorporationInventors: Richard Peter Charles, Brian Cox, Colin David Eldred, Andrew Michael Kenneth Pennell
-
Patent number: 5998388Abstract: This invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. Thus the invention provides compounds of formula (I) which are agonists at the adenosine A1 receptor. ##STR1## wherein R.sup.1 represents phenyl optionally substituted by one or more substituents selected from halogen, C.sub.1-3 alkyl, trifluoromethyl, nitro, cyano, --CO.sub.2 R.sup.a.sub.1 --CONR.sup.a R.sup.b, --COR.sup.a, --SOR.sup.c, --SO.sub.2 R.sup.c, --SO.sub.3 H, --SO.sub.2 NR.sup.a R.sup.b, --OR.sup.a, --NHSO.sub.2 R.sup.c, --NHCOR.sup.a and --NR.sup.a R.sup.b,R.sup.2 represents a C.sub.1-6 alkyl or C.sub.3-6 alkenyl group; R.sup.3 represents C.sub.1-3 alkyl;R.sup.a and R.sup.b may each independently represent hydrogen or C.sub.1-3 alkyl or, when --NR.sup.a R.sup.b is directly attached to said phenyl, R.sup.a and R.sup.Type: GrantFiled: November 6, 1998Date of Patent: December 7, 1999Assignee: Glaxo Wellcome Inc.Inventors: Frank Ellis, Stephen Swanson, Richard Peter Charles, Brian Cox, Andrew Michael Kenneth Pennell, Colin David Eldred